Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Randomized Controlled Study to Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Sponsor: Oneness Biotech Co., Ltd.
A PHASE3 clinical study on Diabetic Foot, this trial is completed. The trial is conducted by Oneness Biotech Co., Ltd. and has accumulated 10 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Feb 2020 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oneness Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Fresno, United States , Guangzhou, China , Guanzhou, China , Jinan, China , Kaohsiung City, Taiwan , Luoyang, China , New Taipei City, Taiwan , Shanghai, China , Suzhou, China , Taichung, Taiwan and 5 more locations